Ivabradine ameliorates doxorubicin-induced cardiotoxicity through improving mitochondrial function and cardiac calcium homeostasis
- PMID: 40112930
- DOI: 10.1016/j.bcp.2025.116881
Ivabradine ameliorates doxorubicin-induced cardiotoxicity through improving mitochondrial function and cardiac calcium homeostasis
Abstract
Doxorubicin (Dox) is a potent anthracycline chemotherapeutic agent. However, its efficacy is limited by its cardiotoxicity, which is driven by excessive oxidative stress, calcium overload, and mitochondrial dysfunction. These mechanisms ultimately result in cardiomyocyte death and cardiac dysfunction. Ivabradine, a hyperpolarization-activated cyclic nucleotide-gated channel blocker, has cardioprotective effects in heart failure and coronary artery disease. However, its potential for mitigating doxorubicin-induced cardiotoxicity (DIC) has not been explored. This study hypothesized that ivabradine reduces cardiac dysfunction in DIC by improving mitochondrial function, restoring calcium homeostasis, and attenuating apoptosis. For in vitro experiments, H9C2 cells were divided into four groups: control, ivabradine (3 μM), Dox (10 μM), and ivabradine co-treated with Dox, with treatments lasting 24 h. Cell viability and mitochondrial function were assessed. For in vivo experiments, male rats (n = 6 per group) were divided into control, ivabradine (10 mg/kg/day, p.o., 30 days), Dox (3 mg/kg, i.p., 6 doses), and ivabradine co-treated with Dox. Cardiac function, mitochondrial function, calcium regulatory proteins, and apoptosis were analyzed. Dox reduced cell viability, increased oxidative stress, and decreased ATP levels in vitro. Co-treatment with ivabradine increased cell viability and reduced oxidative stress but did not restore ATP levels. In rats, Dox impaired mitochondrial function, disrupted mitochondrial dynamics and mitophagy, and altered calcium homeostasis, resulting in cardiomyocyte apoptosis and left ventricular dysfunction. Ivabradine co-treatment attenuated these pathological changes and preserved cardiac function. These findings suggest the potential of ivabradine for cardioprotection against DIC.
Keywords: Cardiotoxicity; Doxorubicin; Intracellular calcium; Ivabradine; Mitochondria.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics.Biochem Pharmacol. 2021 Oct;192:114743. doi: 10.1016/j.bcp.2021.114743. Epub 2021 Aug 26. Biochem Pharmacol. 2021. PMID: 34453902
-
Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis.Pharmacol Res. 2021 Nov;173:105882. doi: 10.1016/j.phrs.2021.105882. Epub 2021 Sep 13. Pharmacol Res. 2021. PMID: 34530122
-
Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.Am J Physiol Cell Physiol. 2019 Aug 1;317(2):C235-C243. doi: 10.1152/ajpcell.00079.2019. Epub 2019 May 22. Am J Physiol Cell Physiol. 2019. PMID: 31116582
-
Cardioprotective strategies against doxorubicin-induced cardiotoxicity: A review from standard therapies to emerging mitochondrial transplantation.Biomed Pharmacother. 2025 Aug;189:118315. doi: 10.1016/j.biopha.2025.118315. Epub 2025 Jul 3. Biomed Pharmacother. 2025. PMID: 40614534 Review.
-
Small Molecules Targeting Mitochondria: A Mechanistic Approach to Combating Doxorubicin-Induced Cardiotoxicity.Cardiovasc Toxicol. 2025 Feb;25(2):216-247. doi: 10.1007/s12012-024-09941-7. Epub 2024 Nov 4. Cardiovasc Toxicol. 2025. PMID: 39495464 Review.
Cited by
-
Targeting AMPK with ivabradine attenuates cyclophosphamide-induced hepatotoxicity: Crosstalk with MAPK, JAK1/STAT3, and PI3K/Akt pathways.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 1. doi: 10.1007/s00210-025-04393-4. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40590918
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources